Advertisement

Clonality Analysis and Tumor of Unknown Primary: Applications in Modern Oncology and Surgical Pathology

  • Liang Cheng
  • Shaobo Zhang
  • Federico A. Monzon
  • Timothy D. Jones
  • John N. Eble
Reference work entry

Abstract

Clonal expansion is the hallmark of neoplasia. Modern cancer models propose that only a minority of tumor stem cells can form new tumors. Unregulated cell growth in cancer cell results from disruption of the regulatory mechanism of stem cell self-renewal. The genetic alterations acquired are inheritable and shared by the entire population of cancer cells that are derived from the same stem cell origin. Carcinogenesis is a stepwise accumulation of gene/epigenetic aberrations in the genome of susceptible stem cells, and the transformed cancer stem cells subsequently expand into more differentiated tumor populations. The clonality of a tumor could be confirmed by concordant X chromosome inactivation, similar pattern of loss of heterozygosity across multiple microsatellite loci, and identical genomic mutation from separate tumor or identical chromosomal alterations. The clonality could be used to define the monoclonal nature of a lesion, define clonal relationship of separate tumors, define the clonal relationship of tumor components in a same tumor, define the clonal relationship between precursors and cancer, or define the clonal relationships between primary and metastatic tumors. The clonality analysis could also be used to identify the tissue contamination, donor origin of a tumor found in transplant recipient, and empower bone marrow engrafting test. Molecular diagnosis of hydatidiform mole and cancer of unknown primary origin is also extensively discussed.

Keywords

Cancer Stem Cell Clonality Analysis Chromosome Inactivation Papillary Renal Cell Carcinoma Clonal Relationship 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Further Reading

  1. Abbosh PH, Wang M, Eble JN, et al. Hypermethylation of tumor suppressor gene CpG Islands in small cell carcinoma of the urinary bladder. Mod Pathol. 2008a;21:355–62.PubMedCrossRefGoogle Scholar
  2. Abbosh PH, Zhang S, MacLennan GT, et al. Germ cell origin of testicular carcinoid tumors. Clin Cancer Res. 2008b;14:1393–6.PubMedCrossRefGoogle Scholar
  3. Allen RC, Zoghbi HY, Moseley AB, et al. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen-receptor gene correlates with X chromosome inactivation. Am J Hum Genet. 1992;51:1229–39.PubMedGoogle Scholar
  4. Anderson GG, Weiss LM. Determining tissue of origin for metastatic cancers: meta-analysis and literature review of immunohistochemistry performance. Appl Immunohistochem Mol Morphol. 2010;18:3–8.PubMedCrossRefGoogle Scholar
  5. Andreoiu M, Cheng L. Multifocal prostate cancer: biological, prognostic, and therapeutic implications. Hum Pathol. 2010;41:781–93.PubMedCrossRefGoogle Scholar
  6. Armstrong AB, Wang M, Eble JN, et al. TP53 mutational analysis supports monoclonal origin of biphasic sarcomatoid urothelial carcinoma (carcinosarcoma) of the urinary bladder. Mod Pathol. 2009;22:113–8.PubMedCrossRefGoogle Scholar
  7. Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–35.PubMedCrossRefGoogle Scholar
  8. Ashworth A, Lord CJ, Reis-Filho JS. Genetic interactions in cancer progression and treatment. Cell. 2011;145:30–8.PubMedCrossRefGoogle Scholar
  9. Bahrami S, Cheng L, Wang M, et al. Clonal relationships between epidermotropic metastatic melanomas and their primary lesions: a loss of heterozygosity and X-chromosome inactivation-based analysis. Mod Pathol. 2007;20:821–7.PubMedCrossRefGoogle Scholar
  10. Barrett MT, Sanchez CA, Prevo LJ, et al. Evolution of neoplastic cell lineages in Barrett oesophagus. Nat Genet. 1999;22:106–9.PubMedCrossRefGoogle Scholar
  11. Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11:726–34.PubMedCrossRefGoogle Scholar
  12. Begum S, Gillison ML, Nicol TL, et al. Detection of human papillomavirus-16 in fine-needle aspirates to determine tumor origin in patients with metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res. 2007;13:1186–91.PubMedCrossRefGoogle Scholar
  13. Belmont JW. Genetic control of X inactivation and processes leading to X-inactivation skewing. Am J Hum Genet. 1996;58:1101–8.PubMedGoogle Scholar
  14. Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 2004;303:848–51.PubMedCrossRefGoogle Scholar
  15. Bishop E, Eble JN, Cheng L, et al. Adrenal myelolipomas show nonrandom X-chromosome inactivation in hematopoietic elements and fat: support for a clonal origin of myelolipomas. Am J Surg Pathol. 2006;30:838–43.PubMedCrossRefGoogle Scholar
  16. Bissell MJ, Hines WC. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med. 2011;17:320–9.PubMedCrossRefGoogle Scholar
  17. Boland CR, Sato J, Appelman HD, et al. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat Med. 1995;1:902–9.PubMedCrossRefGoogle Scholar
  18. Bostwick DG, Shan A, Qian J, et al. Independent origin of multiple foci of prostate intraepithelial neoplasia (PIN): comparison with matched foci of prostate cancer. Cancer. 1998;83:1995–2002.PubMedCrossRefGoogle Scholar
  19. Brandli DW, Ulbright TM, Foster RS, et al. Stroma adjacent to metastatic mature teratoma after chemotherapy for testicular germ cell tumors is derived from the same progenitor cells as the teratoma. Cancer Res. 2003;63:6063–8.PubMedGoogle Scholar
  20. Brunelli M, Eble JN, Zhang S, et al. Gains of chromosomes 7, 17, 12, 16, and 20 and loss of Y occur early in the evolution of papillary renal cell neoplasia: a fluorescent in situ hybridization study. Mod Pathol. 2003a;16:1053–9.PubMedCrossRefGoogle Scholar
  21. Brunelli M, Eble JN, Zhang S, et al. Metanephric adenoma lacks the gains of chromosomes 7 and 17 and loss of Y that are typical of papillary renal cell carcinoma and papillary adenoma. Mod Pathol. 2003b;16:1060–3.PubMedCrossRefGoogle Scholar
  22. Brunelli M, Eble JN, Zhang S, et al. Eosinophilic and classic chromophobe renal cell carcinomas have similar frequent losses of multiple chromosomes from among chromosomes 1, 2, 6, 10, and 17, and this pattern of genetic abnormality is not present in renal oncocytoma. Mod Pathol. 2005;18:161–9.PubMedCrossRefGoogle Scholar
  23. Carrel L, Willard HF. X-inactivation profile reveals extensive variability in X-linked gene expression in females. Nature. 2005;434:400–4.PubMedCrossRefGoogle Scholar
  24. Catto JW, Hartmann A, Stoehr R, et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol. 2006;175:2323–30.PubMedCrossRefGoogle Scholar
  25. Cheng L. Establishing a germ cell origin for metastatic tumors using OCT4 immunohistochemistry. Cancer. 2005;101:2006–10.CrossRefGoogle Scholar
  26. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from prostate cancer patients. J Natl Cancer Inst. 1997;90:233–7.CrossRefGoogle Scholar
  27. Cheng L, Shan A, Cheville JC, et al. Atypical adenomatous hyperplasia of the prostate: a premalignant lesion? Cancer Res. 1998a;58:389–91.PubMedGoogle Scholar
  28. Cheng L, Song SY, Pretlow TG, et al. Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst. 1998b;90:233–7.PubMedCrossRefGoogle Scholar
  29. Cheng L, Leibovich BC, Bergstralh EJ, et al. p53 alteration in regional lymph node metastases from prostate carcinoma: a marker for progression? Cancer. 1999;85:2455–9.PubMedCrossRefGoogle Scholar
  30. Cheng L, Bostwick DG, Li G, et al. Conserved genetic findings in metastatic bladder cancer: a possible utility of allelic loss of chromosomes 9p21 and 17p13 in diagnosis. Arch Pathol Lab Med. 2001a;125:1197–9.PubMedGoogle Scholar
  31. Cheng L, Gu J, Eble JN, et al. Molecular genetic evidence for different clonal origin of components of human renal angiomyolipomas. Am J Surg Pathol. 2001b;25:1231–6.PubMedCrossRefGoogle Scholar
  32. Cheng L, Gu J, Ulbright TM, et al. Precise microdissection of human bladder carcinomas reveals divergent tumor subclones in the same tumor. Cancer. 2002;94:104–10.PubMedCrossRefGoogle Scholar
  33. Cheng L, MacLennan GT, Pan CX, et al. Allelic loss of the active X chromosome during bladder carcinogenesis. Arch Pathol Lab Med. 2004a;128:187–90.PubMedGoogle Scholar
  34. Cheng L, MacLennan GT, Zhang S, et al. Laser capture microdissection analysis reveals frequent allelic losses in papillary urothelial neoplasm of low malignant potential of the urinary bladder. Cancer. 2004b;101:183–8.PubMedCrossRefGoogle Scholar
  35. Cheng L, Thomas A, Roth LM, et al. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004c;28:1341–6.PubMedCrossRefGoogle Scholar
  36. Cheng L, Jones TD, McCarthy RP, et al. Molecular genetic evidence for a common clonal origin of urinary bladder small cell carcinoma and coexisting urothelial carcinoma. Am J Pathol. 2005;166:1533–9.PubMedCrossRefGoogle Scholar
  37. Cheng L, Zhang S, MacLennan GT, et al. Interphase fluorescence in situ hybridization analysis of chromosome 12p abnormalities is useful for distinguishing epidermoid cysts of the testis from pure mature teratoma. Clin Cancer Res. 2006;12:5668–72.PubMedCrossRefGoogle Scholar
  38. Cheng L, Sung MT, Cossu-Rocca P, et al. OCT4: biological functions and clinical applications as a marker of germ cell neoplasia. J Pathol. 2007a;211:1–9.PubMedCrossRefGoogle Scholar
  39. Cheng L, Zhang S, Wang M, et al. Molecular genetic evidence supporting the neoplastic nature of stromal cells in “fibrosis” after chemotherapy for testicular germ cell tumors. J Pathol. 2007b;213:65–71.PubMedCrossRefGoogle Scholar
  40. Cheng L, MacLennan GT, Zhang S, et al. Evidence for polyclonal origin of multifocal clear cell renal cell carcinoma. Clin Cancer Res. 2008;14:8087–93.PubMedCrossRefGoogle Scholar
  41. Cheng L, Zhang S, Davidson DD, et al. Molecular determinants of tumor recurrence in the urinary bladder. Future Oncol. 2009a;5:843–57.PubMedCrossRefGoogle Scholar
  42. Cheng L, Zhang S, MacLennan GT, et al. Molecular and cytogenetic insights into the pathogenesis, classification, differential diagnosis, and prognosis of renal epithelial neoplasms. Hum Pathol. 2009b;40:10–29.PubMedCrossRefGoogle Scholar
  43. Cheng L, Zhang S, Alexander R, et al. Sarcomatoid carcinoma of the urinary bladder: the final common pathway of urothelial carcinoma dedifferentiation. Am J Surg Pathol. 2011a;35:e34–46.PubMedCrossRefGoogle Scholar
  44. Cheng L, Zhang S, Alexander R, et al. The landscape of EGFR pathways and personalized management of nonsmall cell lung cancer. Future Oncol. 2011b;7:519–41.PubMedCrossRefGoogle Scholar
  45. Cheng L, Alexander RE, MacLennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012a;25:347–69.PubMedCrossRefGoogle Scholar
  46. Cheng L, Davidson DD, MacLennan GT, et al. The origins of urothelial carcinoma. Expert Rev Anticancer Ther. 2012b;10:865–80.CrossRefGoogle Scholar
  47. Cheng L, Williamson SR, Zhang S, et al. Understanding the molecular genetics of renal cell neoplasia: implications for diagnosis, prognosis and therapy. Expert Rev Anticancer Ther. 2012c;10:843–64.CrossRefGoogle Scholar
  48. Cheng L, Zhang S, Eble JN, et al. Molecular genetic evidence supporting the neoplastic nature of fibrous stroma in testicular teratoma. Mod Pathol. 2012;25:1432–8.Google Scholar
  49. Cheng L, Zhang S, MacLennan GT, et al. Laser-assisted microdissection in translational research: theory, technical considerations, and future applications. Appl Immunohistochem Mol Morphol. 2012, [Epub ahead of print].Google Scholar
  50. Chin L, Andersen JN, Futreal PA. Cancer genomics: from discovery science to personalized medicine. Nat Med. 2011a;17:297–303.PubMedCrossRefGoogle Scholar
  51. Chin L, Hahn WC, Getz G, Meyerson M. Making sense of cancer genomic data. Genes Dev. 2011b;25:534–55.PubMedCrossRefGoogle Scholar
  52. Cossu-Rocca P, Eble JN, Delahunt B, et al. Renal mucinous tubular and spindle carcinoma lacks the gains of chromosomes 7 and 17 and losses of chromosome Y that are prevalent in papillary renal cell carcinoma. Mod Pathol. 2006a;19:488–93.PubMedCrossRefGoogle Scholar
  53. Cossu-Rocca P, Eble JN, Zhang S, et al. Acquired cystic disease-associated renal tumors: an immunohistochemical and fluorescence in situ hybridization study. Mod Pathol. 2006b;19:780–7.PubMedGoogle Scholar
  54. Cossu-Rocca P, Zhang S, Roth LM, et al. Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis. Mod Pathol. 2006c;19:611–5.PubMedCrossRefGoogle Scholar
  55. Davidson DD, Cheng L. Field cancerization in the urothelium of the bladder. Anal Quant Cytol Histol. 2006;28:337–8.PubMedGoogle Scholar
  56. Dennis JL, Hvidsten TR, Wit EC, et al. Markers of adenocarcinoma characteristic of the site of origin: development of a diagnostic algorithm. Clin Cancer Res. 2005;11:3766–72.PubMedCrossRefGoogle Scholar
  57. Dumur CI, Fuller CE, Blevins TL, et al. Clinical verification of the performance of the pathwork tissue of origin test. Utility and limitations. Am J Clin Pathol. 2011;136:924–33.PubMedCrossRefGoogle Scholar
  58. Emerson RE, Ulbright TM, Zhang S, et al. Nephroblastoma arising in a germ cell tumor of testicular origin. Am J Surg Pathol. 2004;28:687–92.PubMedCrossRefGoogle Scholar
  59. Emerson RE, Wang M, Liu L, et al. Molecular genetic evidence of an independent origin of serous low malignant potential implants and lymph node inclusions. Int J Gynecol Pathol. 2007a;26:387–94.PubMedCrossRefGoogle Scholar
  60. Emerson RE, Wang M, Roth LM, et al. Molecular genetic evidence supporting the neoplastic nature of the Leydig cell component of ovarian Sertoli-Leydig cell tumor. Int J Gynecol Pathol. 2007b;26:368–74.PubMedCrossRefGoogle Scholar
  61. Erlander MG, Ma XJ, Kesty NC, et al. Performance and clinical evaluation of the 92-gene real-time PCR assay for tumor classification. J Mol Diagn. 2011;13:493–503.PubMedCrossRefGoogle Scholar
  62. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61:759–67.PubMedCrossRefGoogle Scholar
  63. Frohling S, Dohner H. Chromosomal abnormalities in cancer. N Engl J Med. 2008;359:722–34.PubMedCrossRefGoogle Scholar
  64. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481:306–13.PubMedCrossRefGoogle Scholar
  65. Green ED, Guyer MS. National human genome research I. Charting a course for genomic medicine from base pairs to bedside. Nature. 2011;470:204–13.PubMedCrossRefGoogle Scholar
  66. Greco FA, Spigel DR, Yardley DA, et al. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist. 2010;15:500–6.PubMedCrossRefGoogle Scholar
  67. Guo Z, Ponten F, Wilander E, et al. Clonality of precursors of cervical cancer and their genetical links to invasive cancer. Mod Pathol. 2000;13:606–13.PubMedCrossRefGoogle Scholar
  68. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell. 2011;145:19–24.PubMedCrossRefGoogle Scholar
  69. Hainsworth JD, Spigel DR, Rubin MS, et al. Treatment of carcinoma of unknown primary site (CUP) directed by molecular profiling diagnosis: a prospective, phase II trial. J Clin Oncol. 2010;28(15 suppl):10540.Google Scholar
  70. Halat S, Eble JN, Grignon DG, et al. Multilocular cystic renal cell carcinoma is a subtype of clear cell renal cell carcinoma. Mod Pathol. 2010;23:931–6.PubMedCrossRefGoogle Scholar
  71. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med. 2010;363:301–4.PubMedCrossRefGoogle Scholar
  72. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.PubMedCrossRefGoogle Scholar
  73. Harris TJ, McCormick F. The molecular pathology of cancer. Nat Rev Clin Oncol. 2010;7:251–65.PubMedCrossRefGoogle Scholar
  74. Heim S, Mandahl N, Mitelman F. Genetic convergence and divergence in tumor progression. Cancer Res. 1988;48:5911–6.PubMedGoogle Scholar
  75. Henley J, Summerlin DJ, Tomich C, et al. Molecular evidence supporting the neoplastic nature of odontogenic keratocyst: a laser capture microdissection study of 15 cases. Histopathology. 2005;47:582–6.PubMedCrossRefGoogle Scholar
  76. Hodges KB, Cummings OW, Saxena R, et al. Clonal origin of multifocal hepatocellular carcinoma. Cancer. 2010;16:4078–85.CrossRefGoogle Scholar
  77. Holiday R. X chromosome reactivation. Nature. 1987;327:661–2.CrossRefGoogle Scholar
  78. Hornberger JC, Amin M, Varadhachary GR, et al. Effect of a gene expression-based tissue of origin test’s impact on patient management for difficult-to-diagnose primary cancers. J Clin Oncol. 2011;29(4 suppl):abstr 459.Google Scholar
  79. Ismael G, de Azambuja E, Awada A. Molecular profiling of a tumor of unknown origin. N Engl J Med. 2006;355:1071–2.PubMedCrossRefGoogle Scholar
  80. Jiang JK, Chen YJ, Lin CH, Yu IT, Lin JK. Genetic changes and clonality relationship between primary colorectal cancers and their pulmonary metastases – an analysis by comparative genomic hybridization. Genes Chromosomes Cancer. 2005;43:25–36.PubMedCrossRefGoogle Scholar
  81. Jones TD, Carr MD, Eble JN, et al. Clonal origin of lymph node metastases in bladder carcinoma. Cancer. 2005a;104:1901–10.PubMedCrossRefGoogle Scholar
  82. Jones TD, Eble JN, Cheng L. Application of molecular diagnostic techniques to renal epithelial neoplasms. Clin Lab Med. 2005b;25:279–303.PubMedCrossRefGoogle Scholar
  83. Jones TD, Eble JN, Wang M, et al. Clonal divergence and genetic heterogeneity in clear cell renal cell carcinomas with sarcomatoid transformation. Cancer. 2005c;104:1195–203.PubMedCrossRefGoogle Scholar
  84. Jones TD, Eble JN, Wang M, et al. Molecular genetic evidence for the independent origin of multifocal papillary tumors in patients with papillary renal cell carcinomas. Clin Cancer Res. 2005d;11:7226–33.PubMedCrossRefGoogle Scholar
  85. Jones TD, Wang M, Eble JN, et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res. 2005e;11:6512–9.PubMedCrossRefGoogle Scholar
  86. Jones TD, Wang M, Sung MT, et al. Clonal origin of metastatic testicular teratomas. Clin Cancer Res. 2006;12:5377–83.PubMedCrossRefGoogle Scholar
  87. Jones TD, Zhang S, Lopez-Beltran A, et al. Urothelial carcinoma with an inverted growth pattern can be distinguished from inverted papilloma by fluorescence in-situ hybridization, immunohistochemistry, and morphologic analysis. Am J Surg Pathol. 2007;31:1861–7.PubMedCrossRefGoogle Scholar
  88. Kaneki E, Oda Y, Ohishi Y, et al. Frequent microsatellite instability in synchronous ovarian and endometrial adenocarcinoma and its usefulness for differential diagnosis. Hum Pathol. 2004;35:1484–93.PubMedCrossRefGoogle Scholar
  89. Katona TM, Jones TD, Wang M, et al. Molecular evidence for independent origin of multifocal neuroendocrine tumors of the enteropancreatic axis. Cancer Res. 2006;66:4936–42.PubMedCrossRefGoogle Scholar
  90. Katona TM, Jones TD, Wang M, et al. Genetically heterogeneous and clonally unrelated metastases may arise in patients with cutaneous melanoma. Am J Surg Pathol. 2007a;31:1029–37.PubMedCrossRefGoogle Scholar
  91. Katona TM, O’Malley DP, Cheng L, et al. Loss of heterozygosity analysis identifies genetic abnormalities in mycosis fungoides and specific loci associated with disease progression. Am J Surg Pathol. 2007b;31:1552–6.PubMedCrossRefGoogle Scholar
  92. Kernek KM, Ulbright TM, Zhang S, et al. Identical allelic losses in mature teratoma and other histologic components of malignant mixed germ cell tumors of the testis. Am J Pathol. 2003;163:2477–84.PubMedCrossRefGoogle Scholar
  93. Kernek KM, Brunelli M, Ulbright TM, et al. Fluorescence in situ hybridization analysis of chromosome 12p in paraffin-embedded tissue is useful for establishing germ cell origin of metastatic tumors. Mod Pathol. 2004;17:1309–13.PubMedCrossRefGoogle Scholar
  94. Kinzler KW, Vogelstein B. Cancer susceptibility genes gatekeepers and caretakers. Nature. 1997;386:761–3.PubMedCrossRefGoogle Scholar
  95. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer. 2001;1:157–62.PubMedCrossRefGoogle Scholar
  96. Kum JB, Grignon DJ, Wang M, et al. Mixed epithelial and stromal tumors of the kidney: evidence for a single cell of origin with capacity for epithelial and stromal differentiation. Am J Surg Pathol. 2011;35:1114–22.PubMedCrossRefGoogle Scholar
  97. Kuperwasser C, Chavarria T, Wu M, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA. 2004;101:4966–71.PubMedCrossRefGoogle Scholar
  98. Lander ES. Initial impact of the sequencing of the human genome. Nature. 2011;470:187–97.PubMedCrossRefGoogle Scholar
  99. Loeb LA. Human cancers express mutator phenotypes: origin, consequences and targeting. Nat Rev Cancer. 2011;11:450–7.PubMedCrossRefGoogle Scholar
  100. Lott S, Wang M, Zhang S, et al. Fibroblast growth factor receptor 3 (FGFR3) and TP53 mutation analysis in inverted urothelial papilloma: Incidence and etiological considerations. Mod Pathol. 2009;22:627–32.PubMedCrossRefGoogle Scholar
  101. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.PubMedCrossRefGoogle Scholar
  102. Lyon MF. Gene action in the X chromosome of the mouse. Nature. 1961;190:327–73.CrossRefGoogle Scholar
  103. Ma XJ, Patel R, Wang X, et al. Molecular classification of human cancer using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med. 2006;130:465–73.PubMedGoogle Scholar
  104. Macconaill LE, Garraway LA. Clinical implications of the cancer genome. J Clin Oncol. 2010;28:5219–28.PubMedCrossRefGoogle Scholar
  105. Maley CC, Galipeau PC, Finley JC, et al. Genetic clonal diversity predicts progression to esophageal adenocarcinoma. Nat Genet. 2006;38:468–73.PubMedCrossRefGoogle Scholar
  106. Manolio TA, Green ED. Genomics reaches the clinic: from basic discoveries to clinical impact. Cell. 2011;147:14–6.PubMedCrossRefGoogle Scholar
  107. McCarthy RP, Wang M, Jones TD, et al. Molecular evidence for the same clonal origin of multifocal papillary thyroid carcinomas. Clin Cancer Res. 2006;12:2414–8.PubMedCrossRefGoogle Scholar
  108. McCarthy RP, Zhang S, Bostwick DG, et al. Molecular genetic evidence for different clonal origins of epithelial and stromal components of phyllodes tumor of the prostate. Am J Pathol. 2004;165:1395–400.PubMedCrossRefGoogle Scholar
  109. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med. 2011;364:340–50.PubMedCrossRefGoogle Scholar
  110. Meyerson M, Gabriel S, Getz G. Advances in understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685–96.PubMedCrossRefGoogle Scholar
  111. Monzon FA, Koen TJ. Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin. Arch Pathol Lab Med. 2010;134:216–24.PubMedGoogle Scholar
  112. Monzon FA, Lyons-Weiler M, Buturovic LJ, et al. Multicenter validation of a 1,550-gene expression profile for identification of tumor tissue of origin. J Clin Oncol. 2009;27:2503–8.PubMedCrossRefGoogle Scholar
  113. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: occult primary (Cancer of Unknown Primary [CUP]). Version 2.2011Google Scholar
  114. Novelli M, Cossu A, Oukrif D, et al. X-inactivation patch size in human female tissue confounds the assessment of tumor clonality. Proc Natl Acad Sci. 2003;100:3311–4.PubMedCrossRefGoogle Scholar
  115. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23–8.PubMedCrossRefGoogle Scholar
  116. O’Malley DP, Orazi A, Wang M, et al. Analysis of loss of heterozygosity and X chromosome inactivation in spleens with myeloproliferative disorders and acute myeloid leukemia. Mod Pathol. 2005;18:1562–8.PubMedGoogle Scholar
  117. O’Malley DP, Orazi A, Dunphy CH, et al. Loss of heterozygosity identifies genetic changes in chronic myeloid disorders, including myeloproliferative disorders, myelodysplastic syndromes and chronic myelomonocytic leukemia. Mod Pathol. 2007;20:1166–71.PubMedCrossRefGoogle Scholar
  118. O’Shaughnessy JA. Molecular signatures predict outcomes of breast cancer. N Engl J Med. 2006;355:615–7.PubMedCrossRefGoogle Scholar
  119. Ohno T, Stribley JA, Wu G, et al. Clonality in nodular lymphocyte-predominant Hodgkin’s disease. N Engl J Med. 1997;337:459–65.PubMedCrossRefGoogle Scholar
  120. Oien KA. Pathologic evaluation of unknown primary cancer. Semin Oncol. 2009;36:8–37.PubMedCrossRefGoogle Scholar
  121. Paterson RF, Ulbright TM, MacLennan GT, et al. Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma. Cancer. 2003;98:1830–6.PubMedCrossRefGoogle Scholar
  122. Pentheroudakis G, Golfinopoulos V, Pavlidis N. Switching benchmarks in cancer of unknown primary: from autopsy to microarray. Eur J Cancer. 2007;43:2026–36.PubMedCrossRefGoogle Scholar
  123. Pillai R, Deeter R, Rigl CT, et al. Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn. 2011;13:48–56.PubMedCrossRefGoogle Scholar
  124. Potti A, Schilsky RL, Nevins JR. Refocusing the war on cancer: the critical role of personalized treatment. Sci Transl Med. 2010;2:28cm13.CrossRefGoogle Scholar
  125. Poulos C, Cheng L, Zhang S, et al. Analysis of ovarian teratomas for isochromosome 12p: evidence supporting a dual histogenetic pathway for teratomatous elements. Mod Pathol. 2006;19:766–71.PubMedGoogle Scholar
  126. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med. 2006;354:2463–72.PubMedCrossRefGoogle Scholar
  127. Ramaswamy S, Ross KN, Lander ES, et al. A molecular signature of metastasis in primary solid tumors. Nat Genet. 2003;33:49–54.PubMedCrossRefGoogle Scholar
  128. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10:992–1000.PubMedCrossRefGoogle Scholar
  129. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol. 2008;26:462–9.PubMedCrossRefGoogle Scholar
  130. Rosenwald S, Gilad S, Benjamin S, et al. Validation of micro-RNA based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol. 2010;23:814–23.PubMedCrossRefGoogle Scholar
  131. Roychowdhury S, Iyer MK, Robinson DR, et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med. 2011;3:111ra21.Google Scholar
  132. Ruiz C, Lenkiewicz E, Evers L, et al. Advancing a clinically relevant perspective of the clonal nature of cancer. Proc Natl Acad Sci USA. 2011;108:12054–9.PubMedCrossRefGoogle Scholar
  133. Schalkwyk LC, Meaburn EL, Smith R, et al. Allelic skewing of DNA methylation is widespread across the genome. Am J Hum Genet. 2010;85:196–212.CrossRefGoogle Scholar
  134. Shackleton M, Quintana E, Fearon ER, et al. Heterogeneity in cancer: cancer stem cells versus clonal evolution. Cell. 2009;138:822–9.PubMedCrossRefGoogle Scholar
  135. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer. 1953;6:963–8.PubMedCrossRefGoogle Scholar
  136. Slaughter DP. Multicentric origin of intraoral carcinoma. Surgery. 1946;20:133–46.PubMedGoogle Scholar
  137. Stancel GA, Coffey D, Alvarez K, et al. Identification of tissue of origin in body fluid specimens with a gene expression microarray assay. Cancer Cytopathol. 2012;120:62–70.PubMedCrossRefGoogle Scholar
  138. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895–904.PubMedCrossRefGoogle Scholar
  139. Stratton MR. Exploring the genomes of cancer cells: progress and promise. Science. 2011;331:1553–8.PubMedCrossRefGoogle Scholar
  140. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–24.PubMedCrossRefGoogle Scholar
  141. Stokes A, Drozdov I, Guerral E, et al. Copy number and loss of heterozygosity detected by SNP array of formalin-fixed tissues using whole-genome amplification. PLoS One. 2011;6:e24503.PubMedCrossRefGoogle Scholar
  142. Sung MT, Eble JN, Wang M, et al. Inverted papilloma of the urinary bladder: a molecular genetic appraisal. Mod Pathol. 2006;19:1289–94.PubMedCrossRefGoogle Scholar
  143. Sung MT, Wang M, Maclennan G, et al. Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation. J Pathol. 2007;211:420–30.PubMedCrossRefGoogle Scholar
  144. Sung MT, Zhang S, MacLennan GT, et al. Histogenesis of clear cell adenocarcinoma in the urinary tract: evidence of urothelial origin. Clin Cancer Res. 2008;14:1947–55.PubMedCrossRefGoogle Scholar
  145. Talmadge JE, Wolman SR, Fidler IJ. Evidence for the clonal origin of spontaneous metastases. Science. 1982;217:361–3.PubMedCrossRefGoogle Scholar
  146. Turhan AG, Humphries RK, Phillips GL, et al. Clonal hematopoiesis demonstrated by X-linked DNA polymorphisms after allogeneic bone marrow transplantation. N Engl J Med. 1989;320:1655–61.PubMedCrossRefGoogle Scholar
  147. Varadhachary GR, Raber MN, Matamoros A, et al. Carcinoma of unknown primary with a colon-cancer profile-changing paradigm and emerging definitions. Lancet Oncol. 2008;9:596–9.PubMedCrossRefGoogle Scholar
  148. Varadhachary GR, Spector Y, Abbruzzese JL, et al. Prospective gene signature study using microRNA to identify the tissue of origin in patients with carcinoma of unknown primary. Clin Cancer Res. 2011;17:4063–70.PubMedCrossRefGoogle Scholar
  149. Velculescu VE, Diaz LA, Jr. Understanding the enemy. Sci Transl Med. 2011;3:98ps37.CrossRefGoogle Scholar
  150. Visvader JE. Cells of origin in cancer. Nature. 2011;469:314–22.PubMedCrossRefGoogle Scholar
  151. Wang X, Jones TD, Zhang S, et al. Amplifications of EGFR gene and protein expression of EGFR, Her-2/neu, c-kit, and androgen receptor in phyllodes tumor of the prostate. Mod Pathol. 2007a;20:175–82.PubMedCrossRefGoogle Scholar
  152. Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor protein expression and gene amplification in small cell carcinoma of the urinary bladder. Clin Cancer Res. 2007b;13:953–7.PubMedCrossRefGoogle Scholar
  153. Wang X, Wang M, MacLennan GT, et al. Evidence for common clonal origin of multifocal lung cancers. J Natl Cancer Inst. 2009;101:560–70.PubMedCrossRefGoogle Scholar
  154. Wareham K, Lyon M, Glenister P, et al. Age related reactivation of an X-linked gene. Nature. 1987;327:725–7.PubMedCrossRefGoogle Scholar
  155. Weber K, Thomaschewski M, Warlich MR, et al. GB marking facilitates multicolor clonal cell tracking. Nat Med. 2011;17:504–9.PubMedCrossRefGoogle Scholar
  156. Weinstein IB, Joe A. Oncogene addiction. Cancer Res. 2008;68:3077–80; discussion 80.PubMedCrossRefGoogle Scholar
  157. Widschwendter M, Fiegl H, Egle D, et al. Epigenetic stem cell signature in cancer. Nat Genet. 2007;39:157–8.PubMedCrossRefGoogle Scholar
  158. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is shared by concurrent prostatic adenocarcinoma and prostatic small cell carcinoma and absent in small cell carcinoma of the urinary bladder: evidence supporting monoclonal origin. Mod Pathol. 2011;24:1120–7.PubMedCrossRefGoogle Scholar
  159. Wong CCY, Caspi A, Williams B, et al. A longitudinal twin study of skewed X chromosome-inactivation. PLoS One. 2011;6:e17873.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Liang Cheng
    • 1
  • Shaobo Zhang
    • 1
  • Federico A. Monzon
    • 2
  • Timothy D. Jones
    • 3
  • John N. Eble
    • 1
  1. 1.Department of Pathology and Laboratory MedicineIndiana University School of MedicineIndianapolisUSA
  2. 2.Departments of Pathology & Immunology and Molecular & Human GeneticsBaylor College of MedicineHoustonUSA
  3. 3.East Louisville Pathologists, PSCLouisvilleUSA

Personalised recommendations